Corvus Pharmaceuticals, Inc. (CRVS) Misses Q4 EPS by 2c

Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) reported Q4 EPS of ($0.14), $0.02 worse than the analyst estimate of ($0.12).

For earnings history and earnings-related data on Corvus Pharmaceuticals, Inc. (CRVS) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• Energy Fuels to acquire rare earth magnet maker VAC for $1.9 billion
• Bristow Group to acquire Berry Aviation for $105 million